Novo Nordisk A/S is hunting for more early-stage deals to pad its pipeline of next-generation obesity drugs, as the drugmaker ...

The drug is under distribution and will be in pharmacies by end of the month, said Vikrant Shrotriya, Novo Nordisk's India ...

By Rishika Sadam and Kashish Tandon HYDERABAD (Reuters) -Danish drugmaker Novo Nordisk launched its blockbuster weight-loss ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Omnicom's $13.5 billion acquisition of rival Interpublic can move forward on the condition the new company does not enter ...

A Chinese-developed GLP-1 drug is as effective as Ozempic or Zepbound, clinical trial says ...

Combining bimagrumab with semaglutide caused 93% of weight loss to come from fat alone By comparison, about 72% of weight ...

Doctors say there have been a number of developments with new weight loss drugs, which could make them easier for patients to ...

Patients who took an experimental drug from Eli Lilly & Co. together with Novo Nordisk A/S’s Wegovy maintained muscle while ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...